ZYNEX INC
zynex.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Nov 17, 2025. Its latest SEC filing is a 4 from Mar 27, 2026.
10-Q for Q3 FY2025, filed Nov 17, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Sells prescription electrical-stimulation devices and rehabilitation products for pain treatment and muscle rehabilitation, marketed to physicians and therapists for patient use.
10-K for FY2024, filed Mar 11, 2025
Who Were Their Customers?
The U.S. field sales force markets devices to physicians and therapists, while products are shipped mainly to patients; a small amount is sold to distributors. Commercial insurers and government payers often pay for insured patients, alongside workers’ compensation and auto claims, hospitals, clinics and private-pay individuals.
10-K for FY2024, filed Mar 11, 2025ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for…View ↗
We sell through a direct sales force in the United States. Our field sales representatives are engaged to sell in predefined geographic…View ↗
Our revenue is derived from several sources including patients with insurance plans held by commercial health insurance carriers or…View ↗
Sales of devices and supplies are primarily shipped directly to the patient, with a small amount of revenue generated from sales to…View ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Nov 17, 2025
−$42.9MView ↗
- ▼ Now a loss
- vs $2.4M in Q3 FY2024
10-Q for Q3 FY2025, filed Nov 17, 2025
Open tableView ↗
-
Mar 26, 2026
Zynex emerges from bankruptcy under new ownership
The Plan Sponsor received all new common shares; existing shares were canceled.
Sources
8-K, filed Mar 26, 2026
On the Effective Date, in connection with the Company’s emergence from the Chapter 11 Cases and in accordance with the terms of the Plan…View ↗
-
Mar 20, 2026
Court confirms the reorganization plan
The plan gives the Plan Sponsor 100% of the reorganized company’s new shares and cancels existing common stock.
Sources
8-K, filed Mar 20, 2026
Pursuant to the Plan, on the Effective Date, the Company Parties will consummate an equity transaction with the Plan Sponsor (an entity…View ↗
-
Feb 19, 2026
Nasdaq delists the company’s common stock
Trading moved to the Pink Limited Market under the symbol ZYXIQ.
Sources
8-K, filed Feb 19, 2026
*On December 17, 2025, Zynex, Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock…View ↗
-
Jan 23, 2026
Thomas Sandgaard is removed as board chair
Steven Dyson was appointed board chair.
Sources
8-K, filed Jan 23, 2026
On January 22, 2026, the Board of Directors of the Company (the “Board”) of Zynex, Inc. (the “Company”) determined to (i) remove Thomas…View ↗
Who Did They Compete With?
Competes with RS Medical, EMSI, and H-Wave
10-K for FY2024, filed Mar 11, 2025Since we are in the market for medical electrotherapy products, we face a mixture of competitors ranging from large manufacturers with…View ↗
Loading...
